Trends in paediatric inflammatory bowel disease‐attributable direct costs: a population‐based analysis

Abstract

SummaryBackgroundIn addition to its morbidities, inflammatory bowel disease (IBD) has a major financial burden on patients and healthcare systems. However, there is a paucity of evidence on IBD‐attributable costs in children.AimsTo determine the trends of IBD‐attributable direct costs over time using a population‐based analysis.MethodsData were extracted from Manitoba Health Provider Claims and other population registry datasets from 1995 to 2017. Children with IBD were matched by age, sex and location with children without IBD. IBD‐attributable direct costs were calculated using utilization counts from the administrative data and cost estimates from different sources. Inpatient hospitalisation and outpatient procedure costs were estimated using the resource intensity weight (RIW) that is attached to each record in the data. Costs were expressed in Canadian dollars.ResultsWe included 733 (428 with Crohn's disease) prevalent cases who were diagnosed with IBD before the age of 18 years and were followed for 2450 person‐years. A matched control group of 6763 persons who were followed for 21 558 person‐years was included. The median annual costs of physician services billed per patient increased from $381 (IQR 215‐1064) in 1995 to $936 (IQR 579‐1932) in 2017 (P < 0.001). The annual medication costs per patient increased from a median of $270 in 1995 to $7944 in 2017 (P < 0.0001). The median annual direct cost per patient was $1810 in 2004 as compared to $14 791 (P < 0.0001) in 2017.ConclusionsOver two decades, there was a significant increase in the paediatric IBD‐attributable direct costs mainly driven by medication costs.